Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Tarsus Pharmaceuticals, Inc. (TARS)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 44,290,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $0 - $0
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Tarsus Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Co.'s primary product candidate, TP-03, is an investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. Co. is developing product candidates to address targeted diseases with unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease, TP-04 for the potential treatment of rosacea, and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 10,506
Total Buy Value $0 $0 $0 $178,661
Total People Bought 0 0 0 2
Total Buy Transactions 0 0 0 2
Total Shares Sold 32,114 94,599 129,599 384,721
Total Sell Value $1,357,161 $4,352,602 $5,265,563 $10,564,551
Total People Sold 3 7 8 9
Total Sell Transactions 3 21 22 41
End Date 2025-03-30 2024-12-27 2024-06-28 2023-06-29

   
Records found: 254
  Page 1 of 11  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Farrow Jeffrey S See Remarks   •       –      –    2025-06-17 4 S $40.42 $550,035 D/D (13,608) 36,704     -
   Farrow Jeffrey S See Remarks   •       –      –    2025-06-16 4 OE $0.00 $0 D/D 27,881 50,312     -
   Lin Elizabeth Yeu Chief Medical Officer   •       –      –    2025-06-16 4 S $41.08 $41,326 D/D (1,006) 7,694     -
   Lin Elizabeth Yeu Chief Medical Officer   •       –      –    2025-06-13 4 OE $0.00 $0 D/D 3,350 8,700     -
   Yarno Wendy L Director   –       •      –    2025-06-13 4 OE $0.00 $0 D/D 3,350 13,700     -
   Morrison Scott W Director   –       •      –    2025-06-13 4 OE $0.00 $0 D/D 3,350 3,350     -
   Link William J Phd Director   –       •      –    2025-06-13 4 OE $0.00 $0 D/D 3,350 170,448     -
   Chaudhuri Bhaskar Director   –       •      –    2025-06-13 4 OE $0.00 $0 D/D 3,350 8,700     -
   Goldberg Andrew D. Director   –       •      –    2025-06-13 4 OE $0.00 $0 D/D 3,350 16,700     -
   Mottiwala Aziz Chief Commercial Officer   •       –      –    2025-06-09 4 AS $43.76 $765,800 D/D (17,500) 47,557     -
   Azamian Bobak R. President/CEO and Board Chair   •       •      –    2025-03-20 4 S $50.11 $427,639 D/D (8,534) 53,635     -
   Wahl Bryan General Counsel   •       –      –    2025-03-20 4 S $50.11 $154,539 D/D (3,084) 51,712     -
   Mottiwala Aziz Chief Commercial Officer   •       –      –    2025-03-20 4 S $50.11 $168,620 D/D (3,365) 65,057     -
   Whitfield Dianne C. Chief Human Resources Officer   •       –      –    2025-03-20 4 S $50.11 $107,085 D/D (2,137) 46,355     -
   Neervannan Seshadri Chief Operating Officer   •       –      –    2025-03-20 4 S $50.11 $122,018 D/D (2,435) 79,682     -
   Farrow Jeffrey S See Remarks   •       –      –    2025-03-20 4 S $50.11 $59,430 D/D (1,186) 22,431     -
   Azamian Bobak R. President/CEO and Board Chair   •       •      –    2025-03-19 4 S $47.40 $405,317 D/D (8,551) 62,169     -
   Wahl Bryan General Counsel   •       –      –    2025-03-19 4 S $47.40 $154,571 D/D (3,261) 54,796     -
   Mottiwala Aziz Chief Commercial Officer   •       –      –    2025-03-19 4 S $47.40 $168,602 D/D (3,557) 68,422     -
   Whitfield Dianne C. Chief Human Resources Officer   •       –      –    2025-03-19 4 S $47.40 $107,077 D/D (2,259) 48,492     -
   Neervannan Seshadri Chief Operating Officer   •       –      –    2025-03-19 4 S $47.40 $120,538 D/D (2,543) 82,117     -
   Farrow Jeffrey S See Remarks   •       –      –    2025-03-19 4 S $47.40 $59,440 D/D (1,254) 23,617     -
   Azamian Bobak R. President/CEO and Board Chair   •       •      –    2025-03-18 4 S $46.29 $330,094 D/D (7,131) 70,720     -
   Wahl Bryan General Counsel   •       –      –    2025-03-18 4 S $46.29 $154,655 D/D (3,341) 58,057     -
   Mottiwala Aziz Chief Commercial Officer   •       –      –    2025-03-18 4 S $46.29 $168,634 D/D (3,643) 71,979     -

  254 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 11
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed